Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
InflaRx NV
IFRX
Healthcare
Biotechnology
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously...
delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:IFRX)
New Post
View:
Posts & Comments
Threaded Posts
(3)
•••
Sokratesaes86
X
Post by
Sokratesaes86
on Jan 09, 2022 10:43am
New COVID Studie Q 1/22
It should also be noted that our other study is now being continued. It would not be published properly yet. The continuation of this study was responsible for the price drop from 40 to the current
...more
(3)
•••
Sokratesaes86
X
Post by
Sokratesaes86
on Jan 09, 2022 10:40am
Ab very very BiG Market
Inflarx sepsis drug. Cost in the US alone. Values from then are now much higher. In 2011, sepsis topped the list of the most cost-intensive conditions in the United States, with total hospital costs
...more
(3)
•••
Sokratesaes86
X
Post by
Sokratesaes86
on Jan 09, 2022 10:36am
Inflarex Countdown to Party
Inflarex IFRX Germany course 3.80 Biopharma Further decision studies will be completed in the 1st half of 2022 including: Vilobelimab is not a Covid drug !!! It combats sepsis caused by Covid, and
...more
(6)
•••
securitynnmotn
X
Post by
securitynnmotn
on Jul 21, 2020 7:58am
ifrx --covid application
https://www.inflarx.de/Home/Investors/Press-Releases.html
(6)
•••
securitynnmotn
X
Post by
securitynnmotn
on Jun 26, 2020 8:29am
ifrx
More specifically, Baker Bros. Advisors was the largest shareholder of InflaRx N.V. (NASDAQ:IFRX), with a stake worth $6.8 million reported as of the end of September. Trailing Baker Bros. Advisors
...more
(6)
•••
securitynnmotn
X
Post by
securitynnmotn
on Jun 25, 2020 8:52pm
ifrx will be the next ino
from $3 to $34 in 6 months
(6)
•••
securitynnmotn
X
Post by
securitynnmotn
on Jun 24, 2020 8:58pm
ifrx
https://www.globenewswire.com/news-release/2020/06/17/2049420/0/en/InflaRx-Reports-Encouraging-Topline-Results-from-the-Exploratory-Phase-II-Part-of-the-Adaptive-Randomized-Phase-II-III-Trial-of-IFX-1
...more
(0)
•••
SS76
X
Post by
SS76
on Jun 28, 2019 12:58pm
$3.15 is a BUY
definitely a buy here, nice accumulation happening, trial updates and new interpretation of anomaly will send this to over $10 in the blink of an eye.
(0)
•••
BerkshireCapGrp
X
Post by
BerkshireCapGrp
on Jun 07, 2019 10:46am
IFRX $3.33 NASDAQ BIOTECH BOUNCE ALERT!
Starting to turn up here. Emotional traders who sold on fear from huge $40++ per share drop on bad news the past few days. This will see a huge bounce. Was $50+ a share not long ago. Company has over
...more
(0)
•••
BerkshireCapGrp
X
Post by
BerkshireCapGrp
on Jun 07, 2019 12:11am
IFRX $3.20 From $40 Huge Bargain!!
IFRX has millions in cash. This has been manipulated on the over reaction and panic due to failed drug trial. This should see a huge bounce from these lows
(216)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Jun 05, 2019 10:45am
it's a buy today for me
bought in at $3.57 per share,seems to be oversold to me,watching the technicals for this one,german biopharma company with a good cash position,so glta.
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >